Tianmei Si

Biographic Data

ID10382085
NAMETianmei Si
GIVEN NAMESTianmei
FAMILY NAMESi
SIGNATURESI T
AFFILIATIONSPeking University Sixth Hospital, Peking University Institute of Mental Health, National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), NHC Key Laboratory of Mental Health (Peking University)
VERIFIEDNo
TOTAL WORKS7
TOTAL CITATIONS0
WORKS AS AUTHOR7
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2019
LATEST PUBLICATION YEAR2026
H-INDEX0

  • Organ-system–based psychiatry education in undergraduate medicine

    Open AccessJinmin Liao, Ni Tang et al.ARTICLEBMC Medical Education2026

    BACKGROUND: Uptake into psychiatry remains modest in many medical education systems, potentially related to limited curricular integration. We implemented an organ-system–based psychiatry module to improve relevance and engagement, evaluating medical students’ satisfaction and subsequent specialty choice. METHODS: This study was conducted in Peking University’s 8-year clinical medicine program, in which students enter directly after high school, …

  • Proteome-wide Mendelian randomization and colocalization analyses identify potential biomarkers for schizophrenia

    Open AccessJingyu Lin, Haiming Huang et al.ARTICLEFrontiers in Psychiatry2026

    This large-scale MR study provides robust evidence supporting causal roles for specific plasma proteins in SCZ pathogenesis, highlighting promising candidates for mechanistic studies and therapeutic development

  • Hedonic capacity in a Chinese community population sample

    Open AccessQi Wang, Yankun Wu et al.ARTICLEBMC Psychology2025

    The Chinese version of the DARS is an effective tool for assessing hedonic capacity, i.e. screening for depression in community-dwelling populations. The observed gender differences in hedonic capacity imply that future mental health services could be more effective if adapted based on gender

  • Effects of aripiprazole on prolactin levels and differences in effectiveness in patients with schizophrenia

    Open AccessQian Li, Yun‐Ai Su et al.ARTICLEFrontiers in Psychiatry2024

    In this real-world study, for patients with acute schizophrenia, aripiprazole was effective in lowering the proportion of patients with abnormal prolactin levels, while it had no significant effect on patients with normal baseline prolactin. After adjusting for factors such as sex, age, prior antipsychotic drugs use history and disease severity, effectiveness and safety of aripiprazole in patients with normal baseline prolactin was significantly …

  • Dose Adjustment Model of Paliperidone in Patients With Acute Schizophrenia

    Open AccessTian-Mei Si, Tianmei Si et al.ARTICLEFrontiers in Psychiatry2021

    This study aimed to investigate the factors that influenced the clinicians to adjust the paliperidone dose in the acute phase of schizophrenia. This was a post hoc study of an 8-week, open-label, single-arm multicenter trial which evaluated the efficacy, safety, and tolerability of flexible doses of paliperidone ER (3-12 mg/day) in patients with acutely exacerbated schizophrenia. Patients were divided into groups according to the dose at week 8 (…

  • Identification of Key Genes and the Pathophysiology Associated With Major Depressive Disorder Patients Based on Integrated Bioinformatics Analysis

    Open AccessGuangyin Zhang, Shixin Xu et al.ARTICLEFrontiers in Psychiatry2020

    Background: At present, laboratory blood tests to support major depressive disorder (MDD) diagnosis are not available. This study aimed to screen potential mRNAs for peripheral blood biomarkers and novel pathophysiology of MDD. Methods: The present study utilized public data from two mRNA microarray datasets to analyze the hub genes changes related to MDD. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway anal…

  • Striatal Functional Connectivity Alterations After Two-Week Antidepressant Treatment Associated to Enduring Clinical Improvement in Major Depressive Disorder

    Open AccessJing An, Le Li et al.ARTICLEFrontiers in Psychiatry2019

    Background: Only less than 40% of patients with Major depressive disorder (MDD) can achieve remission after several weeks of initial antidepressant treatment. Predicting whether the prescribed treatment is effective in the following course may help clinicians modify the treatment regimen in time, and reduce the staggering burden for patients and society. However, there are not yet reliable markers based on neurobiological change after a treatment…